Jeito Capital
Venture capitalParis · 34 people tracked
Investment thesis
Jeito Capital invests in ground-breaking medical innovation with a patient-benefit-driven philosophy, aiming to accelerate patient access to new therapies globally, particularly across Europe and the United States. The firm backs biotech entrepreneurs with significant capital and an integrated, multi-talented team of functional experts spanning clinical, scientific and operational domains. Its stated goal is to help build European champions and market leaders in their respective therapeutic areas, supporting companies through growth stages with deep scientific understanding.
Source: firm website, verified Aug 18, 2026.
Team · 34 people
from the firm's websiteWhat they invest in
from 22 of 31 portfolio companiesBiotech ×22Healthtech ×13Medical Devices ×9Deep Tech ×3Digital Health ×1FemTech ×1Longevity ×1
HQs:United States×6Switzerland×1Denmark×1France×1
Investments · 31 tracked
founders shown can be your intro pathBy year:2025 · 22021 · 13 dated
Advesya is a clinical-stage biotech company developing cancer and autoimmune disease therapies that target IL-1RAP, an antigen upregulated in various cancers and autoimmune conditions.
BiotechHealthtechMedical DevicesBesançon, FR
Christophe Ferrand(Founder and Board Member (Director of R&D))inMarina Deschamps(Founder (Director of CMC))inAndré Baruchel(Founder and Board Member)in
BoardKsenija Pavletic(A.I. Chief Executive Officer)in
Bionyra Pharma is a clinical-stage biopharmaceutical company developing next-generation mono and multispecific antibodies for severe immune-mediated inflammatory diseases, with an initial focus on atopic dermatitis and inflammatory bowel disease.
BiotechHealthtech
Frédéric Marrache(Co-founder & CEO)
NMD Pharma is a clinical-stage biotech company developing first-in-class small-molecule therapies that selectively target skeletal muscle to treat rare neuromuscular diseases and age-related conditions.
BiotechDeep TechHealthtechMedical DevicesAarhus, DK
Odyssey Therapeutics develops small molecule and protein therapeutics targeting upstream signaling nodes and innate immune system mechanisms to prevent pathological inflammation.
BiotechMedical DevicesCambridge, US
Gary D Glick(Executive Officer, Director)
BoardJill Carroll(Director)inCarl Gordon(Director)inValerie Odegard(Director)Jeffrey Leiden(Director)Charles Baum(Director)
Board seatKsenija Pavletic· per SEC Form D
Quell Therapeutics is a clinical-stage biotech company developing engineered regulatory T cell (Treg) therapies using a patient's own cells to restore immune tolerance.
BiotechDeep TechHealthtech
Adcendo develops antibody-drug conjugates (ADCs) targeting cancers with high unmet medical need.
BiotechMedical Devices
Clinical-stage biotech developing anti-CLDN1 ADCs and antibodies for CLDN1+ tumors and fibrotic disease; based in Basel.
Alveus Therapeutics develops next-generation metabolic and obesity therapies, including its lead asset ALV-100 (in Phase 2) and a preclinical amylin pipeline of peptides, oral small molecules, and novel formats aimed at sustainable weight loss with better tolerability.
BiotechHealthtechLongevityPhiladelphia, US
Raj Kannan(Executive Officer, Director)
BoardClaudio Nessi(Director)Ivan Gergel(Director)inJan Van de Bossche(Director)inGarrett Ingram(Director)Gregory Parekh(Director)
Augustine Therapeutics is a biotech company developing HDAC6-targeted therapies for peripheral neuropathies such as Charcot-Marie-Tooth disease and chemotherapy-induced peripheral neuropathy, as well as neurodegenerative disorders like ALS.
BiotechMedical Devices
BiotechCambridge, US
Mohamed Genead(Executive Officer, Director)Michael Tolentino(Executive Officer, Director)David Callanan(Executive Officer)Tarek Hassan(Executive Officer)Derek Kunimoto(Executive Officer)
BoardDavid Guyer(Director)
Azafaros is a clinical-stage biopharmaceutical company developing nizubaglustat, an orally available azasugar with a dual mode of action targeting the central nervous system and glycosphingolipid metabolism.
BiotechMedical Devices
Seattle and Singapore-based biotech developing next-generation multi-payload antibody-drug conjugates for cancer treatment.
Callio Therapeutics develops next-generation dual-payload antibody-drug conjugates (ADCs) with differentiated payload and linker technologies for targeted cancer treatment.
BiotechMedical DevicesSeattle, US
Piers Ingram(President, Co-Founder)Jerome Boyd-Kirkup(Chief Scientific Officer, Co-Founder)Zachary Hornby(Chief Executive Officer)
France-based preclinical biopharma developing first-in-class therapies for heart failure subpopulations.
Corteria Pharmaceuticals develops first-in-class drugs for conditions with high unmet medical need, including worsening and acute decompensated heart failure, right heart failure, sarcopenia, and obesity with complications.
BiotechHealthtech
Global company developing next-generation eye disease therapies; acquired by Merck & Co.
BiotechHolborn, London
James Allister John Costine(Director)Michael Jay Ross(Executive Officer)Catherine Elizabeth Bingham(Director)David Robert Guyer(Executive Officer)
Biotech company developing antibodies to treat autoimmune and inflammatory diseases.
BiotechNew York, US
Carsten Linnemann, PhD(Executive Officer, Director, Promoter)Antonius N.M. Schumacher(Director)Fei Chen(Director)
BoardDavid M. Tanen(Director, Promoter)Helen Kim(Director)
Noema Pharma develops a late-stage portfolio of oral small molecule therapeutics for people with neurological and related disorders, targeting both orphan and larger indications with significant unmet medical needs.
BiotechHealthtechMedical Devices
Ilise Lombardo(Chief Executive Officer)Volker Knappertz(Executive Vice President of Research & Development)Michael Samar(Chief Financial Officer)Rob Lasser(Chief Medical Officer)
Clinical stage company transforming lives in immune mediated disease
Develops gene therapy treatments for Inherited Retinal Diseases regardless of genetic cause.
SparingVision is a genomic medicine company developing gene therapies for ophthalmic diseases, including SPVN06, a neuroprotective gene therapy for retinal conditions.
BiotechDeep TechDigital Health
XyloCor Therapeutics develops gene therapies for advanced coronary artery disease and cardiac damage.
BiotechHealthtechMedical DevicesMalvern, US
Ronald Crystal(Co-founder)Todd Rosengart(Co-founder)John Tucker(President and Chief Executive Officer)Albert Gianchetti(Executive Officer, Director)
BoardGlenn Batchelder(Director)James Cohen(Director)
Exits · 2
IPOs and acquisitions across the tracked portfolioEyeBioacq. by MerckHI-Bioacq. by Biogen
Portfolio news
latest coverage across their companiesCalliotx · funderintel.com · Jul 16, 2026
Adcendo · geekwire.com · Jul 13, 2026
Frequently asked questions
- What sectors does Jeito Capital focus on?
- Jeito Capital focuses on Biotech, Healthtech, Medical Devices.
- Where is Jeito Capital located?
- Jeito Capital is headquartered in Paris, FR.
Media · Podcasts & interviews
featuring the teamGrande Interview - Rafaèle Tordjman (Jeito Capital): Biopharma, le défi clé du financement
BFM Business · Rafaèle Tordjman
Rafaèle Tordjman (Jeito Capital) : Jeito Capital cède Hi-Bio à Biogen
BFM Business · Rafaèle Tordjman
Rafaèle Tordjman (Jeito Capital) : Jeito Capital annonce le premier investissement de 2022
BFM Business · Rafaèle Tordjman
Rafaèle Tordjman (Jeito Capital) : Jeito Capital annonce une levée de fonds de 534 millions d'euros
BFM Business · Rafaèle Tordjman
Rafaèle Tordjman (Jeito Capital): Jeito Capital investit dans des biotechs à dimension européenne
BFM Business · Rafaèle Tordjman

BE SMART - L'interview de Rafaèle Tordjman (Jeito Capital) par Stéphane Soumier
B SMART · Rafaèle Tordjman · youtube.com
Images
Similar investors
ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
B Capital is a venture capital firm that invests in technology and healthcare companies, publishing investment rationale for its portfolio companies.
Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.
Canaan is an early-stage venture capital firm backing founders with transformative ideas across technology and healthcare.
